(Total Views: 401)
Posted On: 02/20/2018 12:08:19 PM
Post# of 106590
TTPH 2.13 FDA NDA decision expected by end of February.
Their phase 3 failed and stock dropped from about $6 to $2+ and trading here the past several days.
The NDA is for the same antbiotic but for a different indication that already has 2 successful trials.
On the CC from 2/13 they said NDA decision is expected as soon as end of February.
IMO near $2+ this is a great opportunity for a bounce back over 3.00 shortly. Take a look
Their phase 3 failed and stock dropped from about $6 to $2+ and trading here the past several days.
The NDA is for the same antbiotic but for a different indication that already has 2 successful trials.
On the CC from 2/13 they said NDA decision is expected as soon as end of February.
IMO near $2+ this is a great opportunity for a bounce back over 3.00 shortly. Take a look
(1)
(0)
